A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naive Patients with Advanced NSCLC

被引：3

作者：

Lisberg, A. ^{[1
]}

Hunt, J. ^{[1
]}

Reese, N. ^{[1
]}

Wang, T. ^{[1
]}

Coluzzi, P. ^{[1
]}

Spiegel, M. ^{[1
]}

Bornazyan, K. ^{[1
]}

Carroll, J. ^{[1
]}

Madrigal, J. ^{[1
]}

Ledezma, B. ^{[1
]}

Mendenhall, M. ^{[1
]}

Bui, J. ^{[1
]}

Lu, H. ^{[1
]}

Cummings, A. ^{[1
]}

Noor, Z. ^{[1
]}

Goldman, J. W. ^{[1
]}

Garon, E. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

EGFR; NSCLC; anti-PD-1; therapy;

D O I：

10.1016/j.jtho.2017.09.456

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA 02.07

引用

页码：S1805 / S1805

页数：1

共 50 条

[1] A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naive patients with advanced NSCLC.
Lisberg, Aaron Elliott
Cummings, Amy Lauren
Goldman, Jonathan Wade
Bornazyan, Krikor
Reese, Nicholas Dean
Wang, Tina
Coluzzi, Paul
Ledezma, Blanca A.
Mendenhall, Melody A.
Jones, Benjamin
Madrigal, John
Carroll, James M.
Gukasyan, Jaklin
Williams, Tawny
Sauer, Lauren
Wells, Courtney L.
Hardy, Ariana R.
Linares, Paulina J.
Adame, Carlos R.
Garon, Edward B.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC
Lisberg, A.
Cummings, A.
Goldman, J. W.
Bornazyan, K.
Reese, N.
Wang, T.
Coluzzi, P.
Ledezma, B.
Mendenhall, M.
Hunt, J.
Wolf, B.
Jones, B.
Madrigal, J.
Horton, J.
Spiegel, M.
Carroll, J.
Gukasyan, J.
Williams, T.
Sauer, L.
Wells, C.
Hardy, A.
Linares, P.
Lim, C.
Ma, L.
Adame, C.
Garon, Edward B.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1138 - 1145
[3] Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC
Wang, P.
Li, Y.
Lv, D.
Ding, L.
Hong, W.
Han-Zhang, H.
Lin, J.
Zhou, J.
Wang, K.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S598 - S599
[4] Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study
Yang, James Chih-Hsin
Lee, Dae Ho
Lee, Jong-Seok
Fan, Yun
De Marinis, Filippo
Okamoto, Isamu
Inoue, Takako
Cid, Jeronimo Rafael Rodriguez
Zhang, Li
Yang, Cheng-Ta
Jimenez, Emmanuel De la Mora
Zhou, Jianying
Perol, Maurice
Lee, Hyeong
Lee, Ki Hyeong
Vicente, David
Ichihara, Eiki
Riely, Gregory J.
Luo, Yiwen
Bhagwati, Niyati Sanat
Lu, Shun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[5] TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC
Rosell, R.
Karachaliou, N.
Cui, J. J.
Chaib, I.
Berenguer, J.
Bratch, J.
Li, X.
Yang, J.
Drozdowskyj, A.
Codony Servat, C.
Codony Servat, J.
Gimenez-Capitan, A.
Viteri, S.
Molina-Vila, M.
Lopez-Vivanco, G.
Vergnenegre, A.
Sanchez-Torres, J. M.
Provencio, M.
De Marinis, F.
Passaro, A.
Carcereny, E.
Reguart, N.
Garcia Campelo, R.
Ignatius Ou, S.
Cardona, A.
Cao, P.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2230 - S2230
[6] Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
Yang, James Chih-Hsin
Lee, Dae Ho
Lee, Jong-Seok
Fan, Yun
de Marinis, Filippo
Okamoto, Isamu
Inoue, Takako
Cid, Jeronimo Rafael Rodriguez
Zhang, Li
Yang, Cheng-Ta
Jimenez, Emmanuel De La Mora
Zhou, Jianying
Perol, Maurice
Lee, Ki Hyeong
Vicente, David
Ichihara, Eiki
Riely, Gregory J.
Luo, Yiwen
Bhagwati, Niyati Sanat
Lu, Shun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA9000 - LBA9000
[7] Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series
Le, Xiuning
Eisert, Anna
Hsia, Te-Chun
Raut, Nirmal Vivek
Ahmad, Azura
Chan, Oscar Siu Hong
De Bondt, Charlotte
Farrugia, David
Froesch, Patrizia
Gonzalez-Cao, Maria
Hendriks, Lizza
Hochmair, Maximilian J.
Mazieres, Julien
O'Sullivan, Hazel
Samol, Jens
van der Wekken, Anthonie J.
Yang, Tsung-Ying
Joshi, Kirti
Vlassak, Soetkin
Chang, Gee-Chen
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
Lam, Wei-Sen
Le, Xiuning
Eisert, Anna
Himpe, Ulrike
De Bondt, Charlotte
Mazieres, Julien
Petrini, Iacopo
Tho, Lye Mun
Ahmad, Azura
Chik, Yin Kwan Jeannie
Chung, Wai
Lee, Kirsty
Yang, Tsung-Ying
Hsia, Te-Chun
Joshi, Kirti
Young, Louise
Berghoff, Karin
Vlassak, Soetkin
Karachaliou, Niki
van der Wekken, Anthonie
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 83 - 84
[9] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
Ahmad, A. R.
Tho, L. M.
Chik, Y. K. J.
Lee, W. C. K.
Yang, T-Y.
Le, X.
Eisert, A. K.
Himpe, U.
De Bondt, C.
Mazieres, J.
Petrini, I.
Lam, W-S.
Joshi, K.
Berghoff, K.
Vlassak, S.
Karachaliou, N.
Van der Wekken, A. J.
Hsia, T-C.
ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
[10] Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
Le, X.
Eisert, A.
Himpe, U.
De Bondt, C.
Mazieres, J.
Petrini, I.
Tho, L. M.
Ahmad, A.
Lam, W. -S.
Chik, Y. K. J.
Lee, W. C. K.
Yang, T. -Y.
Joshi, K.
Berghoff, K.
Vlassak, S.
Karachaliou, N.
v. d. Wekken, A.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S483 - S484

← 1 2 3 4 5 →